Oral Semaglutide Launching in September: New Studies Reveal Risks and Addiction Potential
An oral formulation of semaglutide arriving on the pharmaceutical market this coming September is projected to deliver up to 16.6% weight loss in clinical evaluations, according to data reviewed by medical regulators and public health researchers. This upcoming launch marks a significant shift in the delivery of glucagon-like peptide-1 (GLP-1) receptor agonists, moving patients away … Read more